This statistic displays the number of cases of HIV infections registered in Germany from 2001 to 2022. The number of cases of HIV in Germany dropped significantly in the pandemic-affected years of 2020 and 2021. However, the number of reported cases in 2022 increased again to over 3.2 thousand.
HIV in Europe
In 2022, there were almost 23 thousand diagnoses of HIV cases across EEA. This was an increase of nearly 4.5 thousand compared to 2021. Most cases were recorded among people aged between 30 and 39. All in all, men were the most affected across all age groups.
Transmission mode
New cases of HIV in Europe among females were mostly diagnosed following heterosexual contact. Conversely, the most common HIV transmission mode for men was homosexual contact. People infected with HIV by using illicit drugs in Europe decreased constantly between 2013 and 2021, to increase again in 2022, with 993 cases.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in Germany was reported at 0.1 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Germany - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.
This statistic displays the number of new cases of HIV infection in Germany from 2011 to 2022, by gender. In 2022, the number of new cases of HIV amounted to *** thousand new cases among men and *** thousand new cases among women.
Women's share of population ages 15+ living with HIV of Germany went up by 0.41% from 19.9 % in 2021 to 20.0 % in 2022. Since the 0.80% improve in 2012, women's share of population ages 15+ living with HIV jumped by 13.34% in 2022. Prevalence of HIV is the percentage of people who are infected with HIV. Female rate is as a percentage of the total population with HIV.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Germany DE: Antiretroviral Therapy Coverage: % of People Living with HIV data was reported at 74.000 % in 2017. This stayed constant from the previous number of 74.000 % for 2016. Germany DE: Antiretroviral Therapy Coverage: % of People Living with HIV data is updated yearly, averaging 67.000 % from Dec 2000 (Median) to 2017, with 18 observations. The data reached an all-time high of 74.000 % in 2017 and a record low of 58.000 % in 2006. Germany DE: Antiretroviral Therapy Coverage: % of People Living with HIV data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Germany – Table DE.World Bank.WDI: Health Statistics. Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.; ; UNAIDS estimates.; Weighted average;
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Antiretroviral therapy coverage (% of people living with HIV) in Germany was reported at 87 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. Germany - Antiretroviral therapy coverage (% of people with advanced HIV infection) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.
Attribution-NonCommercial 4.0 (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/
License information was derived automatically
Forecast: Total HIV Incidence Rate in Germany 2023 - 2027 Discover more data with ReportLinker!
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Women's share of population ages 15+ living with HIV (%) in Germany was reported at 20.02 % in 2022, according to the World Bank collection of development indicators, compiled from officially recognized sources. Germany - Female adults with HIV (% of population ages 15+ with HIV) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
BackgroundThe aim of this study is to analyse the prevalence of transmitted drug resistance, TDR, and the impact of TDR on treatment success in the German HIV-1 Seroconverter Cohort.MethodsGenotypic resistance analysis was performed in treatment-naïve study patients whose sample was available 1,312/1,564 (83.9% October 2008). A genotypic resistance result was obtained for 1,276/1,312 (97.3%). The resistance associated mutations were identified according to the surveillance drug resistance mutations list recommended for drug-naïve patients. Treatment success was determined as viral suppression below 500 copies/ml.ResultsPrevalence of TDR was stable at a high level between 1996 and 2007 in the German HIV-1 Seroconverter Cohort (N = 158/1,276; 12.4%; CIwilson 10.7–14.3; p for trend = 0.25). NRTI resistance was predominant (7.5%) but decreased significantly over time (CIWilson: 6.2–9.1, p for trend = 0.02). NNRTI resistance tended to increase over time (NNRTI: 3.5%; CIWilson: 2.6–4.6; p for trend = 0.07), whereas PI resistance remained stable (PI: 3.0%; CIWilson: 2.1–4.0; p for trend = 0.24). Resistance to all drug classes was frequently caused by singleton resistance mutations (NRTI 55.6%, PI 68.4%, NNRTI 99.1%). The majority of NRTI-resistant strains (79.8%) carried resistance-associated mutations selected by the thymidine analogues zidovudine and stavudine. Preferably 2NRTI/1PIr combinations were prescribed as first line regimen in patients with resistant HIV as well as in patients with susceptible strains (susceptible 45.3%; 173/382 vs. resistant 65.5%; 40/61). The majority of patients in both groups were treated successfully within the first year after ART-initiation (susceptible: 89.9%; 62/69; resistant: 7/9; 77.8%).ConclusionOverall prevalence of TDR remained stable at a high level but trends of resistance against drug classes differed over time. The significant decrease of NRTI-resistance in patients newly infected with HIV might be related to the introduction of novel antiretroviral drugs and a wider use of genotypic resistance analysis prior to treatment initiation.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
This scatter chart displays incidence of HIV (per 1,000 uninfected population) against proportion of seats held by women in national parliaments (%) in Germany. The data is filtered where the date is 2021. The data is about countries per year.
HIV Drugs Market Size 2024-2028
The hiv drugs market size is forecast to increase by USD 9.99 billion at a CAGR of 5.02% between 2023 and 2028.
The market is experiencing significant growth due to several key factors. The increasing prevalence of HIV AIDS worldwide continues to drive market expansion. According to the World Health Organization, there were approximately 38 million people living with HIV in 2019. Moreover, expanding access to HIV treatment is another major growth factor. With advancements in HIV treatment, more individuals are able to access life-saving medications. However, drug resistance among individuals poses a significant challenge to the market. As HIV strains become resistant to current treatments, the development of new and effective drugs is crucial. This report provides a comprehensive analysis of these trends and challenges, offering insights into the future growth prospects of the market.
What will be the Size of the HIV Drugs Market During the Forecast Period?
Request Free SampleThe market encompasses a range of pharmaceutical products designed to manage and suppress the viral infection caused by Human Immunodeficiency Virus (HIV). This market has experienced significant growth due to the increasing prevalence of HIV and the ongoing development of new, more effective medications. Notable classes of HIV drugs include those containing CD4 modulators, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, and Epzicom. New product launches continue to drive market expansion, with companies investing in research and development to improve treatment outcomes and patient compliance. The healthcare products industry plays a crucial role In the import and export of HIV medications, ensuring access to these essential treatments for patients worldwide.HIV testing procedures remain a critical aspect of disease management and prevention efforts, further fueling demand for HIV medications withIn the market.
How is this HIV Drugs Industry segmented and which is the largest segment?
The hiv drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. Distribution ChannelOfflineOnlineTherapyCombination HIV medicinesIntegrase inhibitorsNon-nucleoside reverse transcriptase inhibitorsOthersGeographyNorth AmericaCanadaUSEuropeGermanyUKAsiaChinaRest of World (ROW)
By Distribution Channel Insights
The offline segment is estimated to witness significant growth during the forecast period.
Offline distribution channels, including pharmacies, drugstores, hospitals, and clinics, remain a significant segment In the market. Pharmacies and drugstores serve as crucial points of sale for HIV medications, particularly antiretroviral therapy (ART), which is essential for managing HIV/AIDS. The offline distribution segment caters to various patient populations, including those in regions with limited internet access or who prefer face-to-face interactions with healthcare professionals. Key HIV drugs, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, Truvada, Biktavir, Edurant, Aptivus, Kaletra, Lexiva, Norvir, Viracept, Selzentry, Fuzeon, Rukobia, Isentress, Tivicay, Apretude, and Juluca, are distributed offline through these channels.The offline distribution segment's growth is influenced by factors like the prevalence of HIV, testing procedures, and the availability of various HIV medications. Import and export regulations, as well as the increasing demand for healthcare products, further impact this market.
Get a glance at the HIV Drugs Industry report of share of various segments Request Free Sample
The Offline segment was valued at USD 25.82 billion in 2018 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 49% to the growth of the global market during the forecast period.
Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions, Request Free Sample
The North American the market has experienced substantial growth due to advancements in medical research, enhanced healthcare infrastructure, and heightened awareness about HIV/AIDS. With a significant patient population and established healthcare systems In the United States, Canada, and Mexico, North America is a leading market for HIV drugs. Key trends include the development of combination HIV medicines, such as Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, Truvada
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
IntroductionHepatitis B (HBV) and hepatitis C (HCV) viral infections are uncommon in Germany, though these infections have a higher prevalence among certain subpopulations, such as some first-generation migrant groups, people who inject drugs (PWID), and HIV-positive men who have sex with men (HIV+MSM). Repeated estimates of the number of people infected with HBV and HCV are essential to facilitate the monitoring and elimination efforts by 2030. We estimated the total number of people infected with HBV and HCV in Germany, and the number in each specific subpopulation. We based our calculations on data from 2013, a year that we strategically chose to coincide with the availability of data from serological surveys, the advent of highly effective antiviral therapy for HCV, and significant migrant flows in the following years.MethodsWe used the workbook method, a technique that combines subpopulation size and prevalence data. We included different population groups (general population excluding vulnerable groups, migrants stratified by nationality, people who inject opioids (PWIO) and HIV+MSM). We estimated the number of people infected with HBV and the number of people infected with HCV. Estimates of the number of people infected with HBV and HCV are reported with the lower and upper confidence limits.ResultsWe estimated 228,000 (179,000-291,000) HBV-infected adults (≥ 18 years of age) in Germany in 2013, of whom 41% (n = 93,000 [52,000–169,000]) were in the general population excluding vulnerable groups. Another 58% (132,000; 126,000-137,000) were migrants, 1.0% (2,400; 900–6,200) PWIO and 0.4% (1,000; 800–1,400) were HIV+MSM. We estimated 214,000 (135,000–340,000) HCV-infected adults in Germany in 2013, of whom 47% (100,000; 38,000–267,000) were in the general population excluding vulnerable groups, 26.0% (56,000; 47,000–66,000) were migrants, 26% (56,000; 50,000–62,000) were PWIO, and 1.0% (2,500; 2,200–2,800) were HIV+MSM, respectively.DiscussionOur results indicate that more than half of HBV-infected individuals were migrants, and more than half of HCV-infected individuals were PWIO or migrants. This highlights the importance of including relevant subpopulations in national estimates, surveillance, prevention, and therapy. Our estimates serve as a baseline reference for subsequent updates and ongoing monitoring of HBV and HCV epidemiology in Germany.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Germany DE: Incidence of Tuberculosis: per 100,000 People data was reported at 4.800 Ratio in 2023. This records a decrease from the previous number of 5.100 Ratio for 2022. Germany DE: Incidence of Tuberculosis: per 100,000 People data is updated yearly, averaging 6.200 Ratio from Dec 2000 (Median) to 2023, with 24 observations. The data reached an all-time high of 12.000 Ratio in 2000 and a record low of 4.800 Ratio in 2023. Germany DE: Incidence of Tuberculosis: per 100,000 People data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Germany – Table DE.World Bank.WDI: Social: Health Statistics. Incidence of tuberculosis is the estimated number of new and relapse tuberculosis cases arising in a given year, expressed as the rate per 100,000 population. All forms of TB are included, including cases in people living with HIV. Estimates for all years are recalculated as new information becomes available and techniques are refined, so they may differ from those published previously.;World Health Organization, Global Tuberculosis Report.;Weighted average;Aggregate data by groups are computed based on the groupings for the World Bank fiscal year in which the data was released by the World Health Organization. This is the Sustainable Development Goal indicator 3.3.2[https://unstats.un.org/sdgs/metadata/].
Point Of Care (Poc) Hiv Testing Market Size 2024-2028
The point of care (poc) hiv testing market size is forecast to increase by USD 329.8 million at a CAGR of 3.2% between 2023 and 2028.
The market is witnessing significant growth due to several key factors. The increasing prevalence of HIV/AIDS worldwide continues to drive market demand, as early and accurate diagnosis is crucial for effective treatment and management of the disease. Additionally, rising awareness programs for HIV testing, particularly in developing and underdeveloped nations, are expanding access to testing services and boosting market growth. Limited healthcare infrastructure In these regions necessitates the use of PoC HIV testing devices, which offer rapid results and ease of use. These trends are expected to continue shaping the market dynamics In the coming years.
What will be the Size of the Point Of Care (Poc) Hiv Testing Market During the Forecast Period?
Request Free Sample
The market encompasses diagnostic devices and kits designed for rapid HIV testing at patient locations outside of centralized laboratories. With the global HIV/AIDS prevalence rate continuing to rise, there is a growing demand for convenient and quick HIV testing solutions. POC HIV testing is particularly relevant to scenarios involving blood transfusions and donations, as well as in healthcare institutions and home healthcare settings. These tests provide immediate results, enabling timely treatment decisions and improved patient outcomes. The market is also influenced by the increasing prevalence of chronic diseases such as HIV, tuberculosis, and influenza, which necessitate early detection and personalized medicine.
Additionally, demographic trends, including an aging population and increased patient autonomy, are driving the growth of the POC HIV testing market. Despite the advantages, challenges such as turnaround time and cost remain, necessitating ongoing innovation and competition withIn the market.
How is this Point Of Care (Poc) Hiv Testing Industry segmented and which is the largest segment?
The point of care (poc) hiv testing industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
Product
POC HIV testing equipment
POC HIV testing reagents
End-user
Diagnostic labs
Hospitals and clinics
Others
Geography
North America
US
Europe
Germany
UK
France
Asia
China
Rest of World (ROW)
By Product Insights
The poc hiv testing equipment segment is estimated to witness significant growth during the forecast period.
POC HIV testing equipment refers to devices and tools used for HIV testing at or near the patient's care location. This includes rapid HIV test kits, POC HIV viral load testing systems, and POC CD4 count devices. POC testing plays a crucial role in expanding HIV testing access, improving early diagnosis, and increasing linkage to care, particularly in underdeveloped nations and community-based programs. Early diagnosis and swift treatment initiation are essential strategies to combat HIV spread. POC HIV testing equipment advances diagnostics and clinical services, enabling healthcare institutions to provide ART supplies and minimize turnaround time. UNAIDS reports that HIV-related mortality and new infections can be reduced through widespread testing, pre- and post-test counselling, and timely interventions.
Key dynamics driving the POC HIV testing market include chronic diseases, lifestyle-borne diseases, real-time diagnosis, miniaturization of devices, and advanced technologies like biosensors and nanotechnology. Cost-effective, rapid testing is essential for patient management of target diseases, including blood-related disorders and infectious diseases like influenza, HIV, and tuberculosis.
Get a glance at the Point Of Care (Poc) Hiv Testing Industry report of share of various segments Request Free Sample
The POC HIV testing equipment segment was valued at USD 1575.00 million in 2018 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 41% to the growth of the global market during the forecast period.
Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions, Request Free Sample
The market in North America has experienced notable growth due to advancements in medical research, enhanced healthcare infrastructure, and heightened awareness regarding HIV/AIDS. The market caters to the US, Canada, and Mexico, with the region's well-developed healthcare system and thriving industry fueling demand for HIV treatment
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Allemagne: Prevalence of HIV, percent of the population ages 15-49: Pour cet indicateur, La Banque mondiale fournit des données pour la Allemagne de 2010 à 2021. La valeur moyenne pour Allemagne pendant cette période était de 0.1 pour cent avec un minimum de 0.1 pour cent en 2010 et un maximum de 0.1 pour cent en 2010.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Germany DE: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 8.900 NA in 2016. This records a decrease from the previous number of 9.100 NA for 2015. Germany DE: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 9.400 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 11.200 NA in 2000 and a record low of 8.900 NA in 2016. Germany DE: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Germany – Table DE.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Germany DE: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data was reported at 15.200 NA in 2016. This records a decrease from the previous number of 16.000 NA for 2015. Germany DE: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data is updated yearly, averaging 16.700 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 21.100 NA in 2000 and a record low of 15.200 NA in 2016. Germany DE: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Germany – Table DE.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
BackgroundHIV-associated neurocognitive disorders (HAND) are widely present among people living with HIV. Especially its milder forms, asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND), remain highly prevalent worldwide. Diagnosing these conditions is subject to a time and resource consuming neuropsychological assessment. Selecting patients at a higher risk of cognitive impairment by using a simple but effective screening tool helps to organise access to further neuropsychological diagnosis. The International HIV Dementia Scale (IHDS) has until now been a well-established screening tool in African and American countries, however these populations’ demographics defer significantly from ours, so using the same parameters could be ineffective.ObjectivesTo calculate the prevalence of this condition among people attending an HIV outpatient clinic in Berlin and to validate the use of the IHDS as a screening tool for HAND in a German-speaking population.MethodsWe screened 480 HIV-infected patients using the IHDS, 89% of them were on a stable antiretroviral treatment. Ninety of them completed a standardised neuropsychological battery of tests and a specific cognitive complaints questionnaire. The same procedure was applied to a control group of 30 HIV-negative participants. HAND diagnosis was established according to the Frascati criteria.ResultsThe overall prevalence of HAND in our cohort was 43% (20% ANI, 17% MND and 6% HIV-associated dementia). The optimal cut-off on the IHDS for detecting HAND cases was set at 11 and achieved both a sensitivity and a specificity of 80%. When specifically screening for the more severe form of HAND, HIV-associated dementia, a cut-off value of 10 offered an increase in both sensitivity (94%) and specificity (86%). The Youden Index for diagnostic accuracy was 0.6 and 0.8, respectively.ConclusionsThe prevalence of HAND was comparable to the reported by recent studies performed in countries with a similar economic development. The study confirms the IHDS to be a useful HAND screening tool in primary care settings and establishes new recommendations for its use in German-speaking countries.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Germany DE: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 11.600 % in 2021. This records a decrease from the previous number of 11.700 % for 2020. Germany DE: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 12.900 % from Dec 2000 (Median) to 2021, with 22 observations. The data reached an all-time high of 16.100 % in 2000 and a record low of 11.600 % in 2021. Germany DE: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Germany – Table DE.World Bank.WDI: Social: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).;World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).;Weighted average;This is the Sustainable Development Goal indicator 3.4.1 [https://unstats.un.org/sdgs/metadata/].
Sexually Transmitted Diseases Treatment Market Size 2024-2028
The sexually transmitted diseases (STD) treatment market size is forecast to increase by USD 14.3 billion at a CAGR of 4.5% between 2023 and 2028.
The market is experiencing significant growth due to several key factors. The increasing prevalence of STDs worldwide is a major driver for market expansion. According to the World Health Organization, there were an estimated 376 million new cases of curable STDs in 2012. According to the World Health Organization, approximately one million new STD infections occur daily worldwide. Bacterial STDs, such as Chlamydia and Gonorrhea, can be effectively treated with antibiotics. Advances in rapid diagnosis techniques are also contributing to market growth, allowing for earlier detection and treatment of STDs. However, limited healthcare services in developing regions pose a challenge to effective STD treatment, particularly in populations that are most at risk. Despite these challenges, the market is expected to continue growing as efforts to increase awareness and access to healthcare services persist. The market analysis report provides a comprehensive examination of these trends and the factors shaping the future of the STD treatment market.
What will be the Size of the STD Treatment Market During the Forecast Period?
Request Free Sample
The market encompasses a range of contagious and serious conditions that affect the reproductive organs and require medical intervention. Bacterial STDs, such as gonorrhea and syphilis, can be treated with antibiotics, while viral STDs, including HIV/AIDS, hepatitis B, and genital warts, often require antiretroviral drugs or suppressive therapy. Symptoms of these infections can vary from nonexistent to severe, making early diagnosis and treatment crucial to prevent permanent damage and potential complications. The market for STD treatments and infectious disease diagnostics continues to evolve, with ongoing research and development efforts aimed at creating more effective medications and vaccines.
Additionally, antibiotic-resistant strains of gonorrhea and syphilis pose a challenge, necessitating the exploration of alternative treatment options. Antiviral medication and surgical interventions, such as freezing or removal of genital warts, also play a role in managing these conditions. Outbreaks of STDs can lead to increased demand for treatments and heightened awareness of the importance of safe sexual practices. The ongoing global fight against HIV/AIDS and efforts to improve access to STD testing and treatment for underserved populations remain key priorities in the market.
The sexually transmitted diseases (STD) treatment market is evolving with advancements in both pharmaceutical and diagnostic technologies. Antiviral STD drugs and antibiotic STD treatments are essential for managing infections like gonorrhea, chlamydia, and syphilis, with updated syphilis treatment guidelines ensuring more effective care. HIV antiretroviral therapy remains critical for managing HIV, while herpes treatment advancements continue to improve patient outcomes. The HPV vaccine market is also expanding, providing a preventive measure for HPV-related cancers. Bacterial vaginosis drugs and trichomoniasis medication address common infections, while STD rapid test kits and STI prevention therapies are enhancing early detection and prevention efforts. Emerging STD drug research and telemedicine for STD treatment are further improving accessibility and patient care in public health STD initiatives.
How is this Sexually Transmitted Diseases Treatment Industry segmented and which is the largest segment?
The sexually transmitted diseases (STD) treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
Type
Viral infections
Bacterial infections
Others
Geography
North America
US
Europe
Germany
UK
Asia
China
Japan
Rest of World (ROW)
By Type Insights
The viral infections segment is estimated to witness significant growth during the forecast period.
The market is driven by the rise in viral STD infections, such as human papillomavirus (HPV), herpes simplex virus (HSV), hepatitis B virus (HBV), and HIV. According to the Centers for Disease Control and Prevention (CDC), genital HPV infection is the most common STD in the US, affecting approximately 45% of adults aged 18-59 years during 2021-2022. HPV can lead to health complications, including cervical cancer and genital warts. Other viral STDs, such as genital herpes and hepatitis B, can also cause significant health issues. Antiviral medications and suppressive therapy are common treatments for viral STDs, while vaccines are
This statistic displays the number of cases of HIV infections registered in Germany from 2001 to 2022. The number of cases of HIV in Germany dropped significantly in the pandemic-affected years of 2020 and 2021. However, the number of reported cases in 2022 increased again to over 3.2 thousand.
HIV in Europe
In 2022, there were almost 23 thousand diagnoses of HIV cases across EEA. This was an increase of nearly 4.5 thousand compared to 2021. Most cases were recorded among people aged between 30 and 39. All in all, men were the most affected across all age groups.
Transmission mode
New cases of HIV in Europe among females were mostly diagnosed following heterosexual contact. Conversely, the most common HIV transmission mode for men was homosexual contact. People infected with HIV by using illicit drugs in Europe decreased constantly between 2013 and 2021, to increase again in 2022, with 993 cases.